FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3043118032> ?p ?o ?g. }

• W3043118032 endingPage "175" @default.
• W3043118032 startingPage "173" @default.
• W3043118032 abstract "Induced pluripotent stem cells (iPSCs) are mature, differentiated cells that have been genetically reprogrammed to regain a cardinal feature of embryonic stem cells: the ability to re-differentiate into any cell or tissue type in the body. The now-well-established methods of “de-differentiation” enable scientists to transform accessible cells, such as white blood cells or skin fibroblasts, into patient-specific cell lines for even the most hard-to-biopsy tissues, such as the brain and heart. The discovery of human iPSCs in 2007 has fostered novel insights into conditions spanning etiologies and organ systems, from Alzheimer’s disease to Zellweger spectrum disorder.1-3 The hope is that the insights gained from these patient-derived cells will benefit patients through new and improved therapeutics. The field of Clinical Pharmacology has incorporated iPSCs to move that hope toward clinical reality; iPSCs have been used as model systems to understand disease pathology and identify potential therapies (Figure 1). It has been advocated that integration of iPSCs into “organ-on-a-chip” systems will not only improve translatability of drug discovery but will become a diagnostic technology for understanding clinical pharmacology variability and enabling precision medicine.4, 5 In a recent issue of Clinical Pharmacology and Therapeutics, Maciel et al. used iPSC-derived spinal motor neurons from patients with the neurodegenerative disorder Charcot-Marie-Tooth (CMT) disease.6 The iPSCs were cultured as three-dimensional spheroids. Spheroids derived from patients with a specific N98S variant in the NEFL gene had axonal neurofilament deposits that were not observed in control cells derived from those without CMT or with CMT due to a different NEFL variant. The spheroids were then used to test kinase inhibitors for their potential therapeutic effect, identifying two classes of kinase inhibitors that reversed axonal neurofilament accumulation. Thus, iPSC-derived spheroids were demonstrated to be an excellent model system to explore the pathophysiology of CMT and to test potential therapies for this disease. In addition to providing insights to the diseases, iPSCs have been used as “canaries in the coal mine” for early identification of potential drug toxicity. For example, given the known increased incidence of neuropathic side effects to anticancer drugs among patients with CMT, Ohara et al. used iPSCs from patients with CMT to detect compounds that may contribute to neurotoxicity.7 Similarly, Blanchette et al. used population-based iPSC-derived cardiomyocyte models to predict cardiotoxicity, and suggest that iPSCs may be used to conduct the required preclinical “Thorough QT/QTc” studies in a dish.8 These studies leverage genetic susceptibility to develop sensitive screening assays, which may benefit large and diverse patient populations with a myriad of diseases. In this issue of Clinical Pharmacology and Therapeutics, Genova et al. demonstrate another use for iPSCs.9 In this work, iPSCs were generated from patients with the related disorders of immunity ataxia telangiectasia and Aicardi–Goutières syndrome. Neither disease currently has a cure, and available therapies have variable efficacy in treating symptoms. The iPSC lines from affected patients and controls were treated with a battery of immunomodulatory therapies, with careful assessment of biomarkers to determine response. Of particular interest are the observed differences in response to various therapies based on the specific disease (and even disease subtype) of the affected patient. These findings demonstrate the potential for iPSCs to provide a patient-specific assay of drug efficacy, allowing truly personalized and precision therapy. This novel approach may be specifically impactful in rare disease drug development, given the very limited number of clinical subjects.10 Since the discovery of iPSCs, the laboratory techniques used to de-differentiate, re-differentiate, and assay these cells to test important, clinically relevant hypotheses have evolved and matured. New technologies, such as clustered regularly interspaced short palindromic repeats (CRISPR) gene editing have been applied to further enhance the scientific and therapeutic potential of these cells. With continued innovation, more new technologies will continue to be applied, enhancing the use of iPSC for discovery and accelerating those discoveries toward implementation in patient care." @default.
• W3043118032 created "2020-07-23" @default.
• W3043118032 creator A5077172862 @default.
• W3043118032 creator A5087026299 @default.
• W3043118032 date "2020-07-14" @default.
• W3043118032 modified "2023-09-26" @default.
• W3043118032 title "Induced Pluripotent Stem Cells: From the Bedside to the Bench, and Hopefully Back Again" @default.
• W3043118032 cites W1927155785 @default.
• W3043118032 cites W2138977668 @default.
• W3043118032 cites W2557014980 @default.
• W3043118032 cites W2897334536 @default.
• W3043118032 cites W2918257727 @default.
• W3043118032 cites W2987668572 @default.
• W3043118032 cites W2991069968 @default.
• W3043118032 cites W3014424598 @default.
• W3043118032 cites W3021500784 @default.
• W3043118032 doi "https://doi.org/10.1002/cpt.1924" @default.
• W3043118032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32663332" @default.
• W3043118032 hasPublicationYear "2020" @default.
• W3043118032 type Work @default.
• W3043118032 sameAs 3043118032 @default.
• W3043118032 citedByCount "1" @default.
• W3043118032 countsByYear W30431180322020 @default.
• W3043118032 crossrefType "journal-article" @default.
• W3043118032 hasAuthorship W3043118032A5077172862 @default.
• W3043118032 hasAuthorship W3043118032A5087026299 @default.
• W3043118032 hasBestOaLocation W30431180321 @default.
• W3043118032 hasConcept C104317684 @default.
• W3043118032 hasConcept C107459253 @default.
• W3043118032 hasConcept C10854531 @default.
• W3043118032 hasConcept C142724271 @default.
• W3043118032 hasConcept C145103041 @default.
• W3043118032 hasConcept C163763905 @default.
• W3043118032 hasConcept C169760540 @default.
• W3043118032 hasConcept C2779134260 @default.
• W3043118032 hasConcept C28328180 @default.
• W3043118032 hasConcept C54355233 @default.
• W3043118032 hasConcept C60644358 @default.
• W3043118032 hasConcept C71924100 @default.
• W3043118032 hasConcept C74187038 @default.
• W3043118032 hasConcept C86803240 @default.
• W3043118032 hasConcept C95444343 @default.
• W3043118032 hasConceptScore W3043118032C104317684 @default.
• W3043118032 hasConceptScore W3043118032C107459253 @default.
• W3043118032 hasConceptScore W3043118032C10854531 @default.
• W3043118032 hasConceptScore W3043118032C142724271 @default.
• W3043118032 hasConceptScore W3043118032C145103041 @default.
• W3043118032 hasConceptScore W3043118032C163763905 @default.
• W3043118032 hasConceptScore W3043118032C169760540 @default.
• W3043118032 hasConceptScore W3043118032C2779134260 @default.
• W3043118032 hasConceptScore W3043118032C28328180 @default.
• W3043118032 hasConceptScore W3043118032C54355233 @default.
• W3043118032 hasConceptScore W3043118032C60644358 @default.
• W3043118032 hasConceptScore W3043118032C71924100 @default.
• W3043118032 hasConceptScore W3043118032C74187038 @default.
• W3043118032 hasConceptScore W3043118032C86803240 @default.
• W3043118032 hasConceptScore W3043118032C95444343 @default.
• W3043118032 hasIssue "2" @default.
• W3043118032 hasLocation W30431180321 @default.
• W3043118032 hasOpenAccess W3043118032 @default.
• W3043118032 hasPrimaryLocation W30431180321 @default.
• W3043118032 hasRelatedWork W2065653704 @default.
• W3043118032 hasRelatedWork W2087226378 @default.
• W3043118032 hasRelatedWork W2154547515 @default.
• W3043118032 hasRelatedWork W2236280261 @default.
• W3043118032 hasRelatedWork W2253097332 @default.
• W3043118032 hasRelatedWork W2314330663 @default.
• W3043118032 hasRelatedWork W244578021 @default.
• W3043118032 hasRelatedWork W2768952912 @default.
• W3043118032 hasRelatedWork W310828878 @default.
• W3043118032 hasRelatedWork W4360826917 @default.
• W3043118032 hasVolume "108" @default.
• W3043118032 isParatext "false" @default.
• W3043118032 isRetracted "false" @default.
• W3043118032 magId "3043118032" @default.
• W3043118032 workType "article" @default.